<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382105</url>
  </required_header>
  <id_info>
    <org_study_id>11-1818</org_study_id>
    <nct_id>NCT04382105</nct_id>
  </id_info>
  <brief_title>Serum P.Gingivalis Antibodies and Periodontitis</brief_title>
  <official_title>Association Between Serum P.Gingivalis Antibodies and Extent of Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Messina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Messina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to analyze the association between serum P.gingivalis antibodies in
      patients with periodontitis. Furthermore, the objective was to determine if the periodontitis
      influenced serum IgG P.gingivalis antibodies levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty-nine patients with periodontitis and 47 healthy subjects (HS) were enrolled in the
      present study. Enrolled patients were examined and characterized for clinical and blood
      samples analysis, and salivary P.Gingivalis antibodies were expressed and evaluated
      enzyme-linked immunosorbent assay (ELISA) units (EU). The Spearman Correlation Test and
      Jonckheere-Terpstra Test were applied in order to assess the interdependence between serum
      IgG P.gingivalis antibodies and clinical periodontal parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2017</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Attachment Level</measure>
    <time_frame>1-year</time_frame>
    <description>evaluation of changes in clinical attachment level</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">287</enrollment>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>observation of serum P.gingivalis levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis</arm_group_label>
    <description>observation of serum P.gingivalis levels</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation of serum p.gingivalis levels</intervention_name>
    <description>Observation of serum p.gingivalis levels and correlation of plasma p.gingivalis levels with periodontal disease</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Periodontitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Forty-nine patients with periodontitis and 47 healthy subjects (HS) were enrolled in the
        present study. Enrolled patients were examined and characterized for clinical and blood
        samples analysis, and salivary P.Gingivalis antibodies were expressed and evaluated
        enzyme-linked immunosorbent assay (ELISA) units (EU).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of at least 15 teeth

          -  CP with a minimum of 40% of sites with a clinical attachment level (CAL)

             ≥2mm and probing depth (PD) ≥4mm;

          -  Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital
             periapical radiographs

          -  Presence of ≥40% sites with bleeding on probing (BOP)

        Exclusion Criteria:

          -  Intake of contraceptives

          -  Intake of immunosuppressive or anti-inflammatory drugs throughout the last three
             months prior to the study

          -  Status of pregnancy or lactation

          -  Previous history of excessive drinking

          -  Allergy to local anaesthetic

          -  Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin,
             Nifedipine, Cyclosporin A or similar drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Matarese</last_name>
    <role>Study Chair</role>
    <affiliation>University of Messina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Messina</investigator_affiliation>
    <investigator_full_name>Gaetano Isola, DDS, PhD</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>1-year</ipd_time_frame>
    <ipd_access_criteria>Official website</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

